Aerie Pharmaceuticals Inc. shares skyrocketed in the extended session Wednesday after the drug discovery company’s treatment for lowering fluid pressure inside the eyeball yielded promising results. Aerie shares jumped 61% to $34 on heavy volume. In a late-stage clinical trial, the company said its treatment Roclatan significantly lowered intraocular pressures in treated patients compared to those treated with latanoprost or Rhopressa, another Aerie product.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News